Journal
CELLULAR SIGNALLING
Volume 112, Issue -, Pages -Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.cellsig.2023.110889
Keywords
Acute myeloid leukemia (AML); E2A; SDCBP2; Differentiation
Categories
Ask authors/readers for more resources
This study found that SDCBP2 may be a target gene of E2A, and downregulation of SDCBP2 expression can inhibit proliferation and induce differentiation of AML cells. In a mouse model, inhibition of SDCBP2 expression also delayed AML progression.
Acute myeloid leukemia (AML) remains a biologically heterogeneous disease with high morbidity and mortality under the existing treatment strategies. Our previous study showed that E2A might be a potential therapeutic target for AML, but the underlying mechanism was unclear. Here, we found that SDCBP2 might be a target gene of E2A through RNA-seq combined ChIP-seq screening. This was also demonstrated by Co-IP experiment. Furthermore, the expression of E2A and SDCBP2 were increased in both AML cell lines and patient samples. Downregulation of SDCBP2 expression suppressed proliferation and induced differentiation of AML cells. In human xenograft mouse leukemia model, inhibiton of SDCBP2 expression delayed AML progression. Overall, the above results confirmed that SDCBP2 might be a target gene of E2A and a potential therapeutic target for AML.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available